Posted by Michael Wonder on 13 Feb 2023
US FDA issues a CRL for the biologics license application for bevacizumab
12 February 2023 - The US FDA has issued a complete response letter for the biologics license application for bevacizumab filed by our partner Viatris (Mylan).
The complete response letter informs the need for a satisfactory resolution of the observations made during the facility inspection conducted in August, 2022.
